Serious Adverse Events in Patients with Metastatic Renal Cell Carcinoma and ESKD Receiving Systemic Anticancer Therapy: A Real-World Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1258; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "21 patients received ≥1 ICI cycle; 10 received ipilimumab+nivolumab or nivolumab as 1st-line SACT. As SAEs are not routinely captured in RWD, this may limit the evaluation of clinically meaningful outcomes in practice. Observational studies reporting SAEs are warranted to optimize treatment strategies and safety in this cohort."
Adverse events • Clinical • Metastases • Real-world • Real-world evidence • Serious adverse event • Genito-urinary Cancer • Infectious Disease • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease • Septic Shock • Solid Tumor
|
|
Tomaz Milanez; Vinay Srinivasan; Bostjan Seruga; Miha Arnol; Janja Ocvirk; Edgar A. Jaimes
|